Fierce Pharma

OCTOBER 3, 2024

Matthew Walsh, General Manager of Biopharma at ixlayer - the leading cloud-based platform powering an end-to-end, direct-to-patient healthcare solution - sat down with Fierce at Digital Phar | Matthew Walsh, General Manager of Biopharma at Ixlayer – a cloud-based platform specialist empowering operational efficiency, patient access, and improved outcomes (..)

Patients 130

Patients Biopharma Management Pharma 130

MedCity News

JANUARY 3, 2023

By allowing study teams to design and conduct more inclusive and/or relevant studies, real-world data can enhance the standard of care and ultimately improve patient outcomes.

Recruitment 245

Recruitment Leads Patients Biopharma 245

MedCity News

MAY 29, 2023

Ray Therapeutics’ gene therapy is independent of the causative genes driving inherited vision disorders, which CEO Paul Bresge says is important for reaching a broad patient population. Rare disease retinitis pigmentosa is the first disease target, but the startup also plans to test its approach in more prevalent eye disorders.

Leads 279

Leads Patients Biopharma Pharma 279

MedCity News

JUNE 30, 2022

The FDA placed a partial clinical hold on late-stage tests of Sanofi multiple sclerosis drug tolebrutinib after some patients developed drug-induced liver injury. tests are paused, Sanofi said clinical testing in other countries is continuing with additional safety monitoring.

FDA 264

FDA Leads Safety Patients 264

MedCity News

APRIL 21, 2023

The new DEA ruling is doing a disservice not only to people with OUD, but to the entire medical care system—exacerbating a condition that will most likely lead to death.

Physicians 288

Physicians Patients Leads Medical 288

pharmaphorum

DECEMBER 18, 2022

Science has taken a vertical growth trajectory, yet such innovations are, at best, slow to reach the patients in need. We believe that innovation in patient access models is the necessary catalyst to aid patients in starting on and staying on the therapies they need to improve their lives.

Biopharma 98

Biopharma Patients Prescription Medical 98

MedCity News

AUGUST 6, 2024

Its lead program is on track for Phase 2 testing in immunocompromised Covid-19 patients; a preclinical pan-influenza program is in development under a BARDA contract. Apple Tree Partners’ latest startup is Red Queen Therapeutics, developer of stapled peptide drugs that block viral fusion.

Leads 290

Leads Patients Biopharma Pharma 290

European Pharmaceutical Review

AUGUST 14, 2023

Eli Lilly and Company has completed acquisition of two biopharmaceutical companies – Versanis Bio and Sigilon Therapeutics – and their lead assets focused on obesity and diabetes. Lilly announced the successful completion of its acquisition of clinical-stage Versanis Bio and its lead asset bimagrumab, an anti-obesity medicine.

Biopharma 98

Biopharma Leads Medicine Management 98

Pharmaceutical Technology

SEPTEMBER 2, 2022

Forma focuses on researching, developing and marketing new therapies for patients with sickle cell disease (SCD), rare hematologic diseases and cancers. With the takeover, Novo Nordisk will also acquire etavopivat, a lead development candidate of Forma. The board of directors of Forma granted unanimous approval for the deal.

Biopharma 105

Biopharma Leads Patients Pharmaceutical 105

MedCity News

SEPTEMBER 21, 2023

This article explores the benefits of implementing RFID in healthcare settings and how hospitals can gradually transition from barcode to RFID-enabled medication systems, leading to substantial cost savings and improved patient care.

Medical 279

Medical Healthcare Healthcare Leads 279

European Pharmaceutical Review

SEPTEMBER 4, 2023

The biopharma company will be required to seek prior approval before acquiring related products. BIO stated that the settlement will enable the FTC to protect competition, while facilitating rare disease patients to promptly benefit from the deal’s pro-competitive advantages. Divest to invest: the new normal in biopharma?

Competition 98

Competition Biopharma Pharmaceutical Government 98

MedCity News

NOVEMBER 7, 2023

I spent the next seven weeks in a state of utter panic, while also trying to maintain a sense of normalcy for my daughter, who was only four at the time, and work full-time leading marketing for a tech startup. This is despite the fact that, for cancer patients, clinical trials are often considered the best treatment option.

Doctors 317

Doctors Patients Leads Marketing 317

European Pharmaceutical Review

DECEMBER 20, 2023

1 The changes form part of the 2020 Pharmaceutical Strategy for Europe will impact pharma and biopharma companies operating in Europe. The second is an adjustment of unmet need categorisation required for RDP extension; unmet need definition now encompasses ‘meaningful’ impact patient outcomes (notably including quality of life).

Biopharma 98

Biopharma Pharmaceutical Medicine Manufacturing 98

MedCity News

AUGUST 27, 2023

Researchers at the University of Texas MD Anderson Cancer Center published two studies this week on a new approach that could improve treatment for patients with pancreatic cancer. The preclinical studies showed that combining immunotherapy with a KRAS inhibitor can lead to long-lasting tumor elimination.

Leads 246

Leads Patients Biopharma 246

MedCity News

AUGUST 17, 2022

Sanofi breast cancer drug amcenestrant has failed in a Phase 3 clinical trial, leading the pharmaceutical giant to discontinue all clinical development of the small molecule. The move means Sanofi is out of the competitive chase to develop a so-called “oral SERD” therapy for patients with a certain type of breast cancer.

Competition 246

Competition Leads Pharmaceutical Patients 246

MedCity News

SEPTEMBER 13, 2022

The biotech will use the money to advance clinical testing for its lead drug candidate, which seeks to decrease patients’ urinary oxalate, as well as advance its pipeline of preclinical genetically engineered microbes. million in Series B funds.

Engineering 246

Engineering Leads Patients Biopharma 246

MedCity News

SEPTEMBER 20, 2023

This accelerates lead identification and optimization, offering researchers a broader pool of candidates to choose from. Generative AI plays a pivotal role by analyzing genetic, physiological, and clinical data to tailor treatments to individual patients.

Ethics 298

Ethics Medicine Pharmaceutical Pharmaceutical research 298

European Pharmaceutical Review

DECEMBER 3, 2024

We are excited to collaborate with Novartis to accelerate the potential of PTC518 for the hundreds of thousands of [Huntington’s disease] patients worldwide in need of a therapy designed to be well-tolerated and an effective disease-modifying therapy.

Biopharma 59

Biopharma Leads Pharmaceutical Manufacturing 59

Pharmaceutical Technology

MAY 15, 2023

The company’s products Cometriq and Cabometyx are quinoline derivatives developed for the treatment of patients with advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). Zhejiang DTRM Biopharma and Oncore Biopharma stand in second and third positions, respectively.

Leads 92

Leads Biopharma Pharmaceutical Pharma 92

European Pharmaceutical Review

AUGUST 24, 2023

This strategy shift did not occur overnight, but evolved in response to the changing biopharma landscape. Even among the leaders of the biopharma sector, few companies have a significant presence across these platforms, Baral highlighted. The post Divest to invest: the new normal in biopharma?

Biopharma 98

Biopharma Pharmaceutical Pharma Medical 98

European Pharmaceutical Review

MAY 12, 2023

Swedish Orphan Biovitrum AB (Sobi ® ) has agreed to acquire CTI BioPharma for $1.7 There is a large unmet medical need within myelofibrosis, in particular for patients suffering from thrombocytopenia who are inadequately treated by existing medicines.

Food and Drug Administration 105

Food and Drug Administration Biopharma Medicine Food 105

Pharmaceutical Technology

MAY 10, 2023

Swedish Orphan Biovitrum (Sobi) has entered into a definitive agreement to buy biopharmaceutical company CTI BioPharma in an all-cash deal valued at $1.7bn. Vonjo has received the US Food and Drug Administration’s approval to treat myelofibrosis in adult patients with a platelet count below 50 x109/L.

Biopharma 59

Biopharma Food and Drug Administration Food Medicine 59

PM360

SEPTEMBER 15, 2022

The term “patient centricity” has been around for over a decade, and since its first utterance the buzzword has been praised, dissected, criticized, and everything in between. The concept has always been worthwhile, but people within and outside of the industry have wondered whether the industry was truly becoming more patient centric?

Patients 98

Patients Healthcare Healthcare Marketing 98

PM360

AUGUST 9, 2022

Biopharma blockbusters in the last 10 years show a disturbing trend. As a top 10 biopharma company leader shared with us, “Real blockbusters are gone. For biopharma, success in this space will require integrated models that are significantly different than what has been used with historic medicines. In oncology, it’s 47% less.

Biopharma 69

Biopharma Marketing Healthcare Healthcare 69

European Pharmaceutical Review

NOVEMBER 21, 2024

Prior to his work in the biopharma industry, Dr Boshoff was founding Director of the University College London (UCL) Cancer Institute. He will be responsible for “establishing and leading all research priorities within Amgen’s rare disease, oncology, inflammation and cardiometabolic therapeutic areas”, the company explained.

Medicine 59

Medicine Medical science Biopharma Medical 59

Pharmaceutical Technology

JUNE 2, 2023

Rentschler Biopharma has collaborated with Ikarovec for expediting the new gene therapies to treat ophthalmic disease. Under the deal, Rentschler Biopharma’s ATMP facility in Stevenage, UK, will undertake the bioprocess development of adeno-associated virus (AAV) material.

Biopharma 52

Biopharma Manufacturing Leads Pharmaceutical 52

pharmaphorum

AUGUST 5, 2022

Over the past 15 years, more than 60% of asset growth among the top 30 biopharma companies came from acquisitions. Such inorganic growth is no longer viable, argues Pervaise Khan, Accenture’s UK Life Sciences Lead. And of course, all of this will feed into future treatments and positive patient outcomes – the sole purpose of pharma.

Biopharma 52

Biopharma Marketing Pharma Relationship management 52

Pharmaceutical Technology

JANUARY 20, 2023

The demand for mAbs is increasing as they offer patients targeted treatments for a wide range of serious health conditions and diseases. Nevertheless, the potential for mAb therapies in treating medical conditions that have limited options means that biopharma companies are investing considerable resources in development.

Biopharma 52

Biopharma Manufacturing Engineering Specialization 52

Pharmaceutical Technology

MAY 9, 2023

The companies will use the natural product discovery capabilities of Ginkgo Bioworks to expedite the discovery and development of new therapeutic molecules to address diseases with high unmet patient needs.

Biopharma 104

Biopharma Sales Leads Patients 104

European Pharmaceutical Review

SEPTEMBER 27, 2023

Results from Small Pharma’s Phase Ib study in selective serotonin reuptake inhibitor (SSRIs) interaction with SPL026, native N, N-dimethyltryptamine (DMT) has revealed that 92 percent of patients gained remission from major depressive disorder ( MDD ). Currently, SSRIs are the standard of care for MDD.

Pharma 105

Pharma Biopharma Patients Leads 105

pharmaphorum

DECEMBER 16, 2022

The Japanese pharma says it will now start talking to regulatory authorities around the world about potential marketing applications for zolbetuximab as a first-line treatment for patients with locally advanced unresectable or metastatic gastric and gastro-oesophageal (GEJ) cancer. Claudin 18.2 Other companies developing claudin 18.2-targeted

Leads 59

Leads Biopharma Prospecting Patients 59

pharmaphorum

JANUARY 6, 2023

From enabling patient choice during clinical trials to strengthening vital partnerships across the quality ecosystem, connected data will become the lifeblood that enables life sciences teams to collaborate efficiently and effectively in 2023. Patient choice will push sponsors toward operational excellence.

Safety 111

Safety Management Patients Training 111

pharmaphorum

SEPTEMBER 6, 2022

Pleco Therapeutics has closed a first-round financing, raising just over €17 million that it says will fund the development of its lead therapy for acute myeloid leukaemia (AML) through to regulatory filings in the US and EU. million in equity and R&D funding from Belgian biopharma company Hyloris, which was first announced last year.

Leads 103

Leads Biopharma Government Patients 103

European Pharmaceutical Review

OCTOBER 4, 2023

Eli Lilly and Company has agreed to acquire the radiopharmaceutical firm POINT Biopharma Global for $1.4 POINT’s lead programmes are currently in late-stage development. It is being investigated for patients with metastatic castration-resistant prostate cancer (mCRPC) after progression on hormonal treatment.

Biopharma 105

Biopharma Medicine Leads Manufacturing 105

European Pharmaceutical Review

APRIL 2, 2024

On his appointment , Wienand, incoming CEO, Lonza shared: “I am very much looking forward to joining Lonza and leading the company into a strong future… [helping to] serve as a partner of choice for the global biopharma industry in its quest to turn breakthrough innovations into viable therapies. billion.

Biopharma 98

Biopharma Leads Manufacturing Pharmaceutical 98

pharmaphorum

DECEMBER 23, 2022

In 2022, life sciences companies have been hard at work breaking down silos to better serve patients and healthcare professionals (HCPs). With these silos breaking down, biopharmas will have the opportunity to drive a more coordinated approach to HCP engagement using shared data and unified systems, while still maintaining compliance.

Marketing 106

Marketing Sales Medical Patients 106

Pharmaceutical Technology

APRIL 20, 2023

CBC CEO Fu Wei stated: “Hasten is a well-established Chinese biopharma company with tremendous growth potential. Hasten will also use the proceeds from the round to fund future acquisitions. The firm reported 47% growth in sales from Q2 to Q4 in 2022, which is testament to CBC’s unique and effective investor-operator strategy.

Biopharma 98

Biopharma Healthcare Healthcare Sales 98